Krzysztof Kiryluk, MD
Nephrology · New York, NYNPI 1770787251
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,725 of the $7,415 with a category attached, or 77.2%. Novartis accounts for 90.0% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $6,670, more than ten times the $143 reported in 2019.
Across 11 payments — averaging $674.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- Sanofi$566
- Astrazeneca UK Limited$143
- Travere Therapeutics, Inc.$36
Across 5 payments — averaging $1,341,546 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$6.1M
- Vanda Pharmaceuticals Inc.$654K
What the payments were for
- Consulting fees$5,72577%
- Speaking & faculty fees$3254%
- Grants$5668%
- Travel & lodging$4336%
- Food & beverage$3665%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $6,670 |
| Sanofi | 1 | $566 |
| Astrazeneca UK Limited | 4 | $143 |
| Travere Therapeutics, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fabhalta$6,020
How this compares
$7,415 in reported general payments places this provider in the 85th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in New York
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
- Jai RadhakrishnanNew York$369K
- Girish NadkarniNew York$281K
- James ChevalierNew York$202K
- David CharytanNew York$164K
- Kirk CampbellNew York$152K
- Andrew BombackNew York$106K
- Alan PerlmanNew York$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.